BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
⚡ Executive Summary
Last week delivered a regulatory reckoning: the FDA rejected Disc Medicine's bitopertin despite meeting its primary endpoint, issued a Refusal-to-File for Moderna's mRNA flu vaccine, and removed HRT boxed warnings in a signal of the "Makary FDA" era. Meanwhile, BridgeBio's PROPEL 3 data crushed achondroplasia benchmarks, Novocure won pancreatic cancer device approval, and Eli Lilly revealed a $1.5B orforglipron stockpile ahead of its April PDUFA. 👉 Read More
📅 Last Week in Review: Key Events
Moderna RTF Shock: The FDA issued a Refusal-to-File letter for Moderna's mRNA flu vaccine (mRNA-1010), citing the trial's comparator as "insufficient" versus the "best-available standard of care." CBER Director Vinay Prasad personally signed the letter, overruling agency staff. 👉 Read More
NIH Halts Xarelto Arm: The NIH terminated the low-dose rivaroxaban arm of its CAPTIVA stroke trial due to "an increase in safety events and evidence of futility." 👉 Read More
Samsung Bioepis Settlement: Settled with Regeneron to secure a January 2027 U.S. launch for its Eylea biosimilar (Opuviz). 👉 Read More
🟢 BridgeBio Crushes Phase 3: PROPEL 3 delivered +2.10 cm/year mean height velocity and +1.74 cm/year LS mean (p<0.0001) for oral infigratinib. Crucially, it showed the first-ever statistically significant improvement in body proportionality in children under 8. 👉 Read More
🟢 Novocure FDA Approval: Optune Pax approved for locally advanced pancreatic cancer—the first new device for this indication in ~30 years. 👉 Read More
🟢 FDA De-Risks HRT: Removed Boxed Warnings for CV disease, breast cancer, and dementia from six menopausal hormone therapies. Commissioner Makary: "delivering on our promise to make sure women have accurate, scientifically grounded information." 👉 Read More
PTC Translarna Withdrawal: Withdrew its U.S. NDA for Translarna in DMD after FDA indicated data were "unlikely to meet the threshold of substantial evidence."
Lilly Stockpile: Disclosed $1.5B in pre-launch inventory for oral GLP-1 orforglipron, signaling extreme confidence in the April 10 PDUFA.
🔴 Disc Medicine CRL: FDA rejected bitopertin for EPP despite meeting its primary endpoint (40% PPIX reduction). The agency ruled the surrogate marker was "modest" and failed to correlate with clinical outcomes.
🔴 Seres Therapeutics Reboot: Announced a 30% workforce reduction and paused lead program SER-155 to pivot toward earlier-stage immunology. The "microbiome hype cycle" has collapsed into survival mode.
Ultragenyx Restructuring: Announced a 10% workforce reduction (~130 employees) to focus resources on the Angelman syndrome Phase 3 readout.
🔮 Week Ahead (Feb 16–21)
Date | Company/Event | What to Watch |
Mon 2/16 | Markets Closed | President's Day (U.S.). |
Tue 2/17 | Medtronic (MDT) | Q3 FY26 Earnings: Watch Symplicity renal denervation adoption. |
Tue 2/17 | Disc Medicine | Investor call (8am ET) re: CRL and APOLLO trial strategy. |
Wed 2/18 | Analog Devices (ADI) | Healthcare sensor demand as a leading indicator for MedTech. |
Thu 2/19 | PTC Therapeutics | Q4 Earnings: Huntington's pipeline focus post-Translarna. |
Sat 2/21 | Vanda (PDUFA) | FDA decision on Bysanti for bipolar I & schizophrenia. |
💡 Key Themes to Watch
1. The "Makary FDA" Regime Takes Shape
Last week crystallized the new regulatory philosophy: deregulatory on HRT labels, but stringent on surrogate endpoints (Disc Medicine, Moderna). Rare disease CEOs must now prioritize functional, "patient-centered" primary endpoints over purely biochemical ones. 👉 Read More
2. The Oral GLP-1 Race Accelerates
Eli Lilly's $1.5B inventory build signals extreme confidence in orforglipron's April 10 approval. With Novo Nordisk's Wegovy pill already tracking 26,000+ prescriptions in its second week, the oral obesity market is heating up fast. 👉 Read More
3. The Dwarfism "Switch" Trade
BridgeBio's PROPEL 3 data positions oral infigratinib as a potential best-in-class therapy. BioMarin's Voxzogo and Ascendis's TransCon CNP (PDUFA Feb 28) now face competitive repricing pressure. Watch for patient rotation dynamics as BridgeBio targets a 2H 2026 NDA filing. 👉 Read More
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
The "Prasad Signal": Why Portfolios are Being Marked Down 25%
The Moderna RTF wasn't just a rejection; it was a regime change. CBER Director Vinay Prasad personally overruled staff to sign the letter.
This signals the end of the "Surrogate Era." Institutional desks are now aggressively re-screening portfolios for "surrogate-dependent" assets. We identified 3 biomarker-only programs that are now structurally mispriced.
In Today's Pro Brief:
The $1.5B Inventory Gamble: Eli Lilly has stockpiled $1.5B of Orforglipron ahead of the April PDUFA. If the "Prasad Precedent" holds, the write-down triggers a [Pro Users Only]% correction.
BridgeBio vs. The Street: Analysts are modeling a 40% switch rate from Voxzogo. We checked the math on treatment-naïve patients and found the real upside is [Pro Users Only].
The "Makary Alpha": The FDA just quietly removed Boxed Warnings for HRT. We break down the 2 direct beneficiaries poised for a DTC spending spree.
